Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J et al. (2025)
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
J Clin Oncol, JCO2501767 (in press)
DOI 10.1200/JCO-25-01767, PubMed 40779730

Våtsveen TK, Giliberto M, Bjornsdottir V, Centonze F, Besse A, Frey Y, Skånland SS, Tveita A, Alirezaylavasani A, Imbery JF, Misund K, Reiterer V, Zahoor M, Driessen C, Besse L, Tasken K, Schjesvold FH, Farhan H, Munthe LA (2025)
Targeting proteostasis in multiple myeloma through inhibition of LTK
Leukemia (in press)
DOI 10.1038/s41375-025-02682-8, PubMed 40634511

Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, Cook G, Engelhardt M, Delforge M, Hajek R, Schjesvold F, Gay F, Manier S, Weisel KC, Kaiser M, van de Donk NWCJ, Zamagni E, Rodriguez-Otero P, Perrot A, Driessen C, Bila J, Laane E, Dytfeld D, Touzeau C, Beksac M et al. (2025)
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Nat Rev Clin Oncol (in press)
DOI 10.1038/s41571-025-01041-x, PubMed 40624367